If you can’t build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
[ad_1] Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all … Read More